8-K: NKGen Biotech Presents Promising Data on SNK Cell Therapies at H.C. Wainwright Conference

NKGen Biotech highlighted its SNK cell therapy platform and clinical trial results for neurodegenerative diseases and cancer at the H.C. Wainwright 26th Annual Global Investment Conference.

Summary

• NKGen Biotech presented at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, showcasing its Super Natural Killer (SNK) cell therapy platform.
• The company's SNK cell technology is designed to enhance the natural ability of NK cells to identify and eliminate dangerous cells, with applications in both neurodegenerative diseases and cancer.
• NKGen's manufacturing process allows for the production of both autologous and allogeneic SNK cell therapies, with the potential to generate over 100,000 allogeneic doses from a single blood collection.
• The company's GMP facility is 25,000 sq ft, with 12,000 sq ft dedicated to GMP manufacturing, and is CLIA certified and CAP accredited.
• In neurodegenerative diseases, SNK01 has shown promise in reducing amyloid, p-tau, and alpha-synuclein proteins, as well as neuroinflammation markers.
• Compassionate use case studies in Alzheimer's patients have shown improvements in cognitive function and physical abilities after SNK01 treatment.
• Phase I trial data for SNK01 in Alzheimer's disease showed that 90% of patients with mild and moderate AD experienced improved or stable cognitive function.
• A randomized Phase II trial for SNK01 in Alzheimer's disease was launched in August 2024.
• In oncology, SNK01 combined with pembrolizumab showed a synergistic improvement in 2-year survival rates for non-small cell lung cancer (NSCLC) patients.
• Phase I/IIa trial results for SNK01 in TKI-resistant metastatic NSCLC showed a 25% objective response rate and a 100% disease control rate.
• SNK02, an allogeneic NK cell therapy, is being investigated in a Phase I trial for refractory cancer, with initial results presented at ASCO 2024.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook with promising clinical data and a strong technology platform. However, the need for future financing and the risks associated with drug development temper the overall sentiment.

Positives

• NKGen's proprietary manufacturing process allows for large-scale production of both autologous and allogeneic SNK cells.
• The company has a state-of-the-art GMP manufacturing facility.
• SNK01 has demonstrated the ability to reduce key proteins and neuroinflammation markers in neurodegenerative diseases.
• Compassionate use cases have shown remarkable improvements in patients with advanced Alzheimer's disease.
• Clinical trial data suggests SNK01 can improve or stabilize cognitive function in Alzheimer's patients.
• SNK01 has shown synergistic effects when combined with pembrolizumab in treating NSCLC.
• SNK01 has shown promising results in TKI-resistant metastatic NSCLC with a 25% objective response rate.
• The company has a strong intellectual property portfolio with patents granted in key territories.

Negatives

• The company has a history of operating losses and expects significant expenses and continuing losses for the foreseeable future.
• The company's product candidates are still in development and require regulatory approvals.
• The compassionate use case studies have not been validated and may not be predictive of clinical trial results.
• The company is dependent on the success of its SNK natural killer cell technology platform.
• The company faces risks associated with managing clinical trials and regulatory requirements.
• The company needs to raise financing in the future to support its operations and clinical trials.
• SNK02 persistence decreased after repeat dosing and when auto-antibodies were detected.

Risks

• Regulatory approvals for the company's product development may not be obtained, may be delayed, or may be subject to unanticipated conditions.
• The company's ability to manage future growth and clinical trials is uncertain.
• The company is dependent on the success of its SNK natural killer cell technology platform.
• The company faces the risk of not being able to raise sufficient financing in the future.
• The company may not be able to successfully commercialize any product candidates that it develops.
• The company's business, operations, and financial performance are subject to various risks, including unfavorable conditions in the industry and global economy.
• The company faces the risk of not being able to maintain the listing of its stock on the Nasdaq Global Market.
• The company faces the risk of donor specific antibodies developing in all subjects after multiple doses of SNK02.

Future Outlook

The company is focused on advancing its clinical programs for SNK01 in neurodegenerative diseases and cancer, and SNK02 in oncology. They plan to explore SNK02 in combination with immune checkpoint inhibitors and antibody therapy. The company also plans to investigate SNK02 treatment from numerous donors rather than one donor.

Management Comments

• Paul Y. Song, MD, Chairman and CEO, presented the company's slide presentation at the H.C. Wainwright conference.
• Management believes that the future of cancer therapies will be in combination therapies that enable precision targeting, immune activation and immune effector response simultaneously.
• Management believes that SNK cells may provide the missing piece for modular treatment approach regimens that can be easily adapted to include new agents as data become available.

Industry Context

The presentation highlights NKGen's position in the rapidly growing field of cell-based immunotherapies, particularly in the areas of neurodegenerative diseases and cancer. The company's focus on enhancing natural killer cell activity aligns with the broader trend of leveraging the immune system to fight disease. The company is competing with other companies developing cell therapies for similar indications.

Comparison to Industry Standards

• NKGen's approach to using non-genetically modified NK cells is different from some competitors who use genetically modified cells, such as CAR-T therapies.
• The company's ability to produce large quantities of allogeneic NK cells is a key differentiator, as many cell therapies are limited by manufacturing challenges.
• The compassionate use case studies in Alzheimer's disease show promising results, but these need to be confirmed in larger, controlled clinical trials, similar to the approach taken by companies like Biogen with their Alzheimer's drug, Lecanemab.
• The 2-year survival data for SNK01 combined with pembrolizumab in NSCLC is competitive with other combination therapies in the market, such as those involving checkpoint inhibitors and chemotherapy.
• The 25% objective response rate in TKI-resistant NSCLC is comparable to other targeted therapies in this difficult-to-treat patient population.
• The company's focus on both autologous and allogeneic therapies provides flexibility in addressing different patient needs, similar to the strategies employed by companies like Allogene Therapeutics.

Stakeholder Impact

• Shareholders may be positively impacted by the promising clinical data and potential for future growth.
• Employees may benefit from the company's expansion and success.
• Patients with neurodegenerative diseases and cancer may benefit from the development of new treatment options.
• Customers may benefit from the company's products and services.
• Suppliers may benefit from the company's growth and increased demand for their products.
• Creditors may benefit from the company's financial stability and ability to repay debts.

Next Steps

• The company will continue to advance its clinical programs for SNK01 in neurodegenerative diseases and cancer.
• The company will continue to advance its clinical programs for SNK02 in oncology.
• The company will explore SNK02 in combination with immune checkpoint inhibitors and antibody therapy.
• The company will investigate SNK02 treatment from numerous donors rather than one donor.
• The company will provide an updated PFS for the SNK01 Phase I/IIa Clinical Trial in TKI resistant metastatic NSCLC at a later date.

Key Dates

Keywords

SNK cells, natural killer cells, immunotherapy, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, cancer, non-small cell lung cancer, clinical trials, biomarkers, pembrolizumab, allogeneic, autologous, GMP manufacturing